Table I.
Associations between miR-29a or IFITM3 and the clinicopathological characteristics in 52 HCC cases.
| miR-29a | IFITM3 | ||||||
|---|---|---|---|---|---|---|---|
| Clinicopathologic characteristics | (n) | Overexpression (n) | Nonoverexpression (n) | P-value | Overexpression (n) | Nonoverexpression (n) | P-value |
| Age (years) | 0.686 | 0.330 | |||||
| ≤51 | 24 | 9 | 15 | 15 | 9 | ||
| >51 | 28 | 9 | 19 | 21 | 7 | ||
| Sex | 0.245 | 0.683 | |||||
| Male | 37 | 11 | 26 | 25 | 12 | ||
| Female | 15 | 7 | 8 | 11 | 4 | ||
| Tumor size (cm) | 0.005 | 0.005 | |||||
| ≤5 | 21 | 12 | 9 | 10 | 11 | ||
| >5 | 31 | 6 | 25 | 26 | 5 | ||
| TNM stage | 0.703 | 0.309 | |||||
| I–II | 27 | 10 | 17 | 17 | 10 | ||
| III–IV | 25 | 8 | 17 | 19 | 6 | ||
| Tumor encapsulation | 0.115 | 0.115 | |||||
| Absent | 28 | 7 | 21 | 22 | 6 | ||
| Present | 24 | 11 | 13 | 14 | 10 | ||
| Tumor multifocal | 0.001 | 0.049 | |||||
| Absent | 22 | 13 | 9 | 12 | 10 | ||
| Present | 30 | 5 | 25 | 24 | 6 | ||
| Venous invasion | <0.001 | <0.001 | |||||
| Absent | 21 | 13 | 8 | 9 | 12 | ||
| Present | 31 | 5 | 26 | 27 | 4 | ||
| HBsAg | |||||||
| Negative | 13 | 6 | 7 | 0.313 | 7 | 6 | 0.165 |
| Positive | 39 | 12 | 27 | 29 | 10 | ||
| AFP (ng/ml) | 0.542 | 0.209 | |||||
| ≤400 | 29 | 9 | 20 | 18 | 11 | ||
| >400 | 23 | 9 | 14 | 18 | 5 | ||
| Cirrhosis | 0.278 | 0.734 | |||||
| Absent | 18 | 8 | 10 | 13 | 5 | ||
| Present | 34 | 10 | 24 | 23 | 11 | ||
The P-value represents probabilities for miR-29a or IFITM3 expression between variable subgroups determined by χ2 test. IFITM3, interferon-induced transmembrane protein 3; HCC, hepatocellular carcinoma; AFP, α-fetoprotein; HBsAg, hepatitis B surface antigen; TNM, tumor-node-metastasis; n, number of cases.